Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (currently amended) A method of treating cancer comprising administering to a patient in need thereof an effective amount of a compound of Formula I:



(I)

wherein,

each R is independently hydrogen, hydroxy, alkyl, aryl, cycloalkyl, heteroaryl, alkoxy, heterocyclic or amino;

each R_1 is independently alkyl, halo, alkoxy, haloalkyl, haloalkoxy, cycloalkyl, heterocyclic, hydroxy, -C(O)-R_8, -NR_9R_{10}, -$NR_9C(O)$-R_{12} or –$C(O)NR_9R_{10}$;

each R_2 is independently alkyl, aryl, heteroaryl, –C(O)-R_8 or SO_2R'', where R'' is alkyl, aryl, heteroaryl, NR_9N_{10} or alkoxy;

each R_5 is independently hydrogen, alkyl, aryl, haloalkyl, cycloalkyl, heteroaryl, heterocyclic, hydroxy, -C(O)-R_8 or $(CHR)_rR_{11}$;

X is O or S;

j is 0 or 1;

p is 0, 1, 2 or 3;

q is 0, 1 or 2;

r is 0, 1, 2 or 3;

R_8 is hydroxy, alkyl, aryl, heteroaryl, alkoxy, cycloalkyl or heterocyclic;

R_9 and R_{10} are independently hydrogen, alkyl, aryl, aminoalkyl, heteroaryl, cycloalkyl and heterocyclic, or R_9 and R_{10} together with N may form a ring, where the ring atoms are selected from the group consisting of C, N, O and S;

R_{11} is hydroxy, amino, monosubstituted amino, disubstituted amino, alkyl, aryl, heteroaryl, alkoxy, cycloalkyl or heterocyclic

R_{12} is alkyl, aryl, heteroaryl, alkoxy, cycloalkyl or heterocyclic; and

Z is hydroxy, -O-alkyl, or $-NR_3R_4$, where R_3 and R_4 are independently hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, or heterocyclic, or R_3 and R_4 may combine with N to form a ring where the ring atoms are selected from the group consisting of CH_2, N, O and S, or



wherein Y is independently CH_2, O, N or S, Q is C or N, n is independently 0, 1, 2, 3 or 4, and m is 0, 1, 2 or 3;

or a pharmaceutically acceptable salt, hydrate or solvate thereof, in combination with at least one chemotherapeutic agent selected from the group consisting of microtubule interference agents, topoisomerase inhibitors, alkylating agents, thymidylate synthase inhibitors, irreversible steroidal aromatase inactivators, anti-metabolites, pyrimidine antagonists, purine antagonists, ribonucleotide reductase inhibitors, and kinase inhibitors,

wherein the cancer is breast cancer, small cell lung cancer or colon cancer.

2. (original) The method of claim 1, wherein R_1 is halo and p is 1.

3. (original) The method of claim 1, wherein R_1 is F or Cl and p is 1.

4. (original) The method of claim 1, wherein Z is $-NR_3R_4$ wherein R_3 and R_4 are lower alkyl or form a morpholine ring.

5. (original) The method of claim 1, wherein Z is:



wherein each Y is CH_2, each n is 2, m is 0 and R_3 and R_4 form a morpholine ring.

6. (original) The method of claim 1, wherein R_2 is methyl and q is 2, wherein the methyls are bonded at the 3 and 5 positions.

7. (original) The method of claim 1, wherein the compound of formula I is selected from the group consisting of









and



and pharmaceutically acceptable salts, solvates and hydrates thereof.

8. (original) The method of claim 1, wherein the compound of formula I is selected from the group consisting of:

















and



and pharmaceutically acceptable salts, solvates and hydrates thereof.

9. (original) The method of claim 1, wherein the compound of Formula (I) is:



or a pharmaceutically acceptable salt, solvate or hydrate thereof.

10. (original) The method of claim 9, wherein the salt is a malate salt.

11. (original) The method of claim 1, wherein the at least one chemotherapeutic agent is selected from the group consisting of taxanes, vinca alkyloids, topoisomerase I inhibitors and topoisomerase II inhibitors.

12. (original) The method of claim 1, wherein the at least one chemotherapeutic agent is selected from the group consisting of paclitaxel, docetaxel, vinblastine, vincristine, vindesine, irinotecan, doxorubicin, epirubicin, leucovorin, etopside, teniposide, idarubicine, gemcitabine, daunorubicin, carboplatin, cisplatin, oxaliplatin, chlorambucil, melphalan, cyclophosphamide, ifosfamide, temozolomide, thiotepa, mitomycin C, busulfan, carmustine, lomustine, 5-fluorouracil, capecitabine, exemestane, methotrexate, trimetrexate, fluorouracil, fluorodeoxyuridine, azacytidine, mercaptopurine, thioguanine, pentostatin, cytarabine, fludarabine, hydroxyurea, bevacizumab, cetuximab, gefitinib and imatinib.

13 - 16. (canceled)

17. (currently amended) A method of treating cancer comprising administering to a patient in need thereof an effective amount of a compound selected from the group consisting of:

5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide;

5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide;

5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-morpholin-4-yl-ethyl)-amide;

(S)-5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-morpholin-4-yl-propyl)-amide;

(R)-5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-morpholin-4-yl-propyl)-amide;

5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-morpholin-4-yl-propyl)-amide;

5-(5-Chloro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-morpholin-4-yl-propyl)-amide;

5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylamino-ethyl)-amide; and

3-[3,5-dimethyl-4-(4-morpholin-4-yl-piperidine-1-carbonyl)-1H-pyrrol-2-methylene]-5-fluoro-1,3-dihydro-indol-2-one,

or a pharmaceutically acceptable salt, hydrate or solvate thereof, in combination with at least one chemotherapeutic agent selected from the group consisting of microtubule interference agents, topoisomerase inhibitors, alkylating agents, thymidylate synthase inhibitors, irreversible steroidal aromatase inactivators, anti-metabolites, pyrimidine antagonists, purine antagonists, ribonucleotide reductase inhibitors, and kinase inhibitors,

wherein the cancer is breast cancer, small cell lung cancer or colon cancer.

18. (original) The method of claim 17, wherein the at least one chemotherapeutic agent is selected from the group consisting of taxanes, vinca alkyloids, topoisomerase I inhibitors and topoisomerase II inhibitors.

19. (original) The method of claim 17, wherein the at least one chemotherapeutic agent is selected from the group consisting of paclitaxel, docetaxel, vinblastine, vincristine, vindesine, irinotecan, doxorubicin, epirubicin, leucovorin, etopside, teniposide, idarubicine, gemcitabine, daunorubicin, carboplatin, cisplatin, oxaliplatin, chlorambucil, melphalan, cyclophosphamide, ifosfamide, temozolomide, thiotepa, mitomycin C, busulfan, carmustine, lomustine, 5-fluorouracil, capecitabine, exemestane, methotrexate, trimetrexate, fluorouracil, fluorodeoxyuridine, azacytidine, mercaptopurine, thioguanine, pentostatin, cytarabine, fludarabine, hydroxyurea, bevacizumab, cetuximab, gefitinib and imatinib.

20. (canceled)

21. (new) A method of treating cancer comprising administering to a human in need thereof an effective amount of a compound selected from the group consisting of:

5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide;

5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide;

5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-morpholin-4-yl-ethyl)-amide;

(S)-5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-morpholin-4-yl-propyl)-amide;

(R)-5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-morpholin-4-yl-propyl)-amide;

5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-morpholin-4-yl-propyl)-amide;

5-(5-Chloro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-hydroxy-3-morpholin-4-yl-propyl)-amide;

5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-ethylamino-ethyl)-amide; and

3-[3,5-dimethyl-4-(4-morpholin-4-yl-piperidine-1-carbonyl)-1H-pyrrol-2-methylene]-5-fluoro-1,3-dihydro-indol-2-one,

or a pharmaceutically acceptable salt, hydrate or solvate thereof, in combination with at least one chemotherapeutic agent selected from the group consisting of docetaxel, 5-fluorouracil, doxorubicin, cisplatin and irinotecan,

wherein the cancer is breast cancer, small cell lung cancer or colon cancer.

22. (new) The method of claim 21, wherein the cancer is breast cancer and the at least one chemotherapeutic agent is docetaxel, 5-fluorouracil or doxorubicin.

23. (new) The method of claim 21, wherein the cancer is small cell lung cancer and the at least one chemotherapeutic agent is cisplatin.

24. (new) The method of claim 21, wherein the cancer is colon cancer and the at least one chemotherapeutic agent is irinotecan.

25. (new) A method of treating breast cancer comprising administering to a human in need thereof an effective amount of 5-(5-Fluoro-2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylamino-ethyl)-amide or a pharmaceutically acceptable salt, hydrate or solvate thereof, in combination with docetaxel.